Literature DB >> 23171856

Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis.

Da-Ni Zhong1, Ji-Zhou Wu, Guo-Jian Li.   

Abstract

AIMS: Bisphosphonate-related osteonecrosis of the jaws (BONJ) is a severe complication in patients on bisphosphonate therapy. The study was conducted to verify the association between CYP2C8 (rs1934951) polymorphism and BONJ predisposition.
METHODS: The relative epidemiologic studies were identified in PubMed and Embase to conduct a meta-analysis using STATA.
RESULTS: In the pooled analysis with multiple cancer types, patients carrying the CYP2C8 rs1934951 AA or AG genotype showed no significantly increased BONJ susceptibility compared with those carrying the wild GG genotype [dominant: odds ratio (OR) = 2.05, 95% confidence interval (CI) = 0.67-6.29, p = 0.209; recessive: OR = 1.88, 95% CI = 0.23-15.6, p = 0.560; AG vs. GG: OR = 2.07, 95% CI = 0.80-5.32, p = 0.133, and AA vs. GG: OR = 1.34, 95% CI = 0.48-3.74, p = 0.578]. A significant association between AA and AG genotypes of CYP2C8 (rs1934951) and BONJ risk was found in the subgroup analysis of multiple myeloma (dominant: OR = 5.77, 95% CI = 1.21-27.63, p = 0.028; AG vs. GG: OR = 5.02, 95% CI = 2.06-12.23, p = 0.001, and AA vs. GG: OR = 16.23, 95% CI = 1.72-78.7, p = 0.015).
CONCLUSION: The results indicated that AA and AG genotypes of CYP2C8 (rs1934951) might be predictors for multiple myeloma patients at high risk to develop BONJ.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23171856     DOI: 10.1159/000342120

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

2.  Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.

Authors:  Catherine Van Poznak; Evan L Reynolds; Cherry L Estilo; Mimi Hu; Bryan Paul Schneider; Daniel L Hertz; Christina Gersch; Jacklyn Thibert; Dafydd Thomas; Mousumi Banerjee; James M Rae; Daniel F Hayes
Journal:  Oral Dis       Date:  2020-12-14       Impact factor: 3.511

Review 3.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

4.  Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics.

Authors:  Jee-Hwan Kim; Yong Jae Ko; Ji-young Kim; Yoonsoo Oh; Jihye Hwang; Sangjin Han; Sanguk Kim; Jae-Hoon Lee; Dong-Hoo Han
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

5.  The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.

Authors:  Xiangkun Wang; Tingdong Yu; Xiwen Liao; Chengkun Yang; Chuangye Han; Guangzhi Zhu; Ketuan Huang; Long Yu; Wei Qin; Hao Su; Xiaoguang Liu; Tao Peng
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.